A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Denosumab (Primary)
- Indications Advanced breast cancer; Bone metastases; Male breast cancer
- Focus Therapeutic Use
- 22 Oct 2018 Status changed from recruiting to discontinued due to low accrual.
- 31 Aug 2018 Biomarkers information updated
- 23 Mar 2017 Status changed from not yet recruiting to recruiting.